Podcast: HIV PrEP for Women
Key Decisions in HIV Care: PrEP Considerations in Cisgender Women

Released: March 24, 2022

Expiration: March 23, 2023

Activity

Progress
1
Course Completed

In this episode from the series “Key Decisions in HIV Care,” Latesha Elopre, MD, MSPH, and Karine Lacombe, MD, PhD, discuss important considerations for PrEP in cisgender women, including:

  • Discussion of the PrEP gap and racial and gender disparities in PrEP access
  • CDC, EACS, and WHO guidance on PrEP eligibility
  • PrEP regimens currently recommended for adults and adolescents including FTC/TDF daily, FTC/TAF daily, and long-acting cabotegravir
  • Data from phase III trials on the efficacy of FTC/TDF daily for women including Partners PrEP, TDF, VOICE, and FEM-PrEP
  • Pharmacokinetic data of FTC/TDF and FTC/TAF in the female genital tract and discussion of why on-demand dosing of FTC/TDF is not recommended in cisgender women
  • Data and recommendations for the use of the dapivirine ring from ASPIRE and The Ring Study and their open-label extensions, DREAM and HOPE
  • Data from the HPTN084 study on the use of long-acting cabotegravir as PrEP for cisgender women
  • Recommendations for the use of PrEP during pregnancy and breastfeeding
  • Clinical monitoring and considerations during PrEP use